

- 12) Sato T, Okumura F, Ariga T, Hatakeyama S. TRIM6 interacts with Myc and maintains the pluripotency of mouse embryonic stem cells. *J Cell Sci.* 2012, 125:1544-55.
- 13) Yamada M, Okura Y, Suzuki Y, Fukumura S, Miyazaki T, Ikeda H, Takezaki S, Kawamura N, Kobayashi I, Ariga T. Somatic mosaicism in two unrelated patients with X-linked chronic granulomatous disease characterized by the presence of a small population of normal cells. *Gene.* 2012, 497:110-5.

## 2. 学会発表

- 1) Yamazaki Y, Yamada M, Takezaki S, Kato M, Park M-J, Maruyama K, Chida N, Ohara O, Kobayashi I, Ariga T. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. XVth meeting of the European Society for Immunodeficiencies (ESID) ( Oct 3-6, 2012, Florence, Italy.)
- 2) Miyawaki T, Kanegane H, Imai K, Yamada M, Takada H, Nonoyama S, Ariga T, Bexon T, Rojavin M, Kobayashi M, Hara T: Efficacy and safety of Hizentra, a subcutaneous immune globulin, in Japanese patients with primary immunodeficiency diseases. XVth meeting of the European Society for Immunodeficiencies (ESID) ( Oct 3-6, 2012, Florence, Italy.)
- 3) Iguchi A, Sugiyama M, Terashita Y, Ohshima J, Cho Y, Ariga T. Pre-engraftment syndrome after stem cell transplantation is associated with early complications, such as acute graft-versus-host disease, veno-occlusive disease, and intracranial haemorrhage. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) (April 1-5, 2012, Geneva, Switzerland.)

## H. 知的財産権の出願・登録状況

### 1. 特許取得

なし

### 2. 実用新案登録

なし

### 3. その他

なし

### Ⅲ 研究成果の刊行に関する一覧

雑誌

発表者名	論文タイトル名	発表雑誌	巻号	ページ	出版年
Ma CS, Avery DT, Chan A, Batten M, Bustamante J, Boisson-Dupuis S, Arkwright PD, Minegishi Y, Nonoyama S, French MA, Choo S, Peake J, Wong M, Cook MC, Fulcher DA, Casanova JL, Deenick EK, Tangye SG.	Functional STAT3 deficiency compromises the generation of human T follicular helper cells.	Blood.	26:119	3997-4008	2012
Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, Takagi M, Mizutani S, Morio T.	The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils.	Nat Immunol.	26:13	369-378	2012
Ishida H, Imai K, Homma K, Tamura S, Imamura T, Itoh M, Nonoyama S.	GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia.	Eur J Pediatr.	171	1273-1276	2012
Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Walker Minz R, Sehgal S.	Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, north India.	Asian Pac J Allergy Immunol	30	71-78	2012
Nozaki T, Takada H, Ishimura M, Ihara K, Imai K, Morio T, Kobayashi M, Nonoyama S, Hara T.	Endocrine complications in primary immunodeficiency diseases in Japan.	Clin Endocrinol.	77	628-634	2012
Kawai T, Saito M, Nishikomori R, Yasumi T, Izawa K, Murakami T, Okamoto S, Mori Y, Nakagawa N, Imai K, Nonoyama S, Wada T, Yachie A, Ohmori K, Nakahata T, Heike T.	Multiple reversions of an IL2RG mutation restore T cell function in an X-linked severe combined immunodeficiency patient.	J Clin Immunol.	32	690-697	2012
Nakaoka H, Kanegane H, Taneichi H, Miya K, Yang X, Nomura K, Takezaki S, Yamada M, Ohara O, Kamae C, Imai K, Nonoyama S, Wada T, Yachie A, Hershfield MS, Ariga T, Miyawaki T.	Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis.	Int J Hematol.	95	692-696	2012
Oshima K, Nagase T, Imai K, Nonoyama S, Obara M, Mizukami T, Nunoi H, Kanegane H, Kuribayashi F, Amemiya S, Ohara O.	A dual reporter splicing assay using HaloTag-containing proteins.	Curr Chem Genomics.	in press		2012
Kakiuchi S, Nonoyama S, Wakamatsu H, Kogawa K, Wang L, Kinoshita-Yamaguchi H, Takayama-Ito M, Lim CK, Inoue N, Mizuguchi M, Igarashi T, Saijo M.	Neonatal herpes encephalitis caused by a virologically confirmed acyclovir resistant herpes simplex virus type 1.	J. Clin. Microbiol.	in press		2012
Yang X, Kanegane H, Nishida N, Imamura T, Hamamoto K, Miyashita R, Imai K, Nonoyama S, Sanayama K, Yamaide A, Kato F, Nagai K, Ishii E, Zelm M, Latour S, Zhao X, Miyawaki T.	Clinical and genetic characteristics of XIAP deficiency in Japan.	J Clin Immunol.	32	411-420	2012
Kobayashi D, Kogawa K, Imai K, Tanaka T, Sada A, Nonoyama S.	Hyper-eosinophilia in granular acute B-cell lymphoblastic leukemia with myeloid antigen expression.	Pediatr Int.	54	543-546	2012
Kakiuchi S, Nonoyama S, Wakamatsu H, Kogawa K, Wang L, Kinoshita-Yamaguchi H, Takayama-Ito M, Lim CK, Inoue N, Mizuguchi M, Igarashi T, Saijo M.	Neonatal herpes encephalitis caused by a virologically confirmed acyclovir resistant herpes simplex virus type 1.	J Clin Microbiol.	in press		2012
Wada T, Muraoka M, Toma T, Imai T, Shigemura T, Agematsu K, Haraguchi K, Moriuchi H, Oh-Ishi T, Kitoh T, Ohara O, Morio T, Yachie A.	Rapid Detection of Intracellular p47phox and p67phox by Flow Cytometry: Useful Screening Tests for Chronic Granulomatous Disease.	J Clin Immunol.	in press		2012
Hori T, Ohnishi H, Teramoto T, Tsubouchi K, Naiki T, Hirose Y, Ohara O, Seishima M, Kaneko H, Fukao T, Kondo N.	Autosomal-Dominant Chronic Mucocutaneous Candidiasis with STAT1-Mutation can be Complicated with Chronic Active Hepatitis and Hypothyroidism.	J Clin Immunol.	32(6)	1213-1220	2012
Takezaki S, Yamada M, Kato M, Park MJ, Maruyama K, Yamazaki Y, Chida N, Ohara O, Kobayashi I, Ariga T.	Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain.	J Immunol.	189(3)	1521-1526	2012
Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Minz RW, Sehgal S.	Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India.	Asian Pac J Allergy Immunol.	30(1)	71-78	2012
Mohammadzadeh I, Yeganeh M, Aghamohammadi A, Parvaneh N, Behniafard N, Abolhassani H, Tabassomi F, Hemmat M, Kanegane H, Miyawaki T, Ohara O, Rezaei N.	Severe primary antibody deficiency due to a novel mutation of mu heavy chain.	J Investig Allergol Clin Immunol.	22(1)	78-79	2012
Hiramoto T, Ebihara Y, Mizoguchi Y, Nakamura K, Yamaguchi K, Ueno K, Mochizuki S, Yamamoto S, Nagasaki M, Furukawa Y, Tani K, Nakauchi H, Kobayashi M, Tsuji K	Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia-derived pluripotent stem cells with heterozygous ELANE mutation.	ProcNatl Acad Sci USA	in press		2013
Kawai T, Nishikomori R, Izawa K, Murata Y, Tanaka N, Sakai H, Saito M, Yasumi T, Takaoka Y, Nakahata T, Mizukami T, Nunoi H, Kiyohara Y, Yoden A, Murata T, Sasaki S, Ito E, Akutagawa H, Kawai T, Imai C, Okada S, Kobayashi M, Heike T.	Frequent somatic mosaicism of NEMO in T cells of patients with X-linked anhidrotic ectodermal dysplasia with immunodeficiency.	Blood	119(23)	5458-66	2012

Kobayashi Y, Matsui H, Kanai A, Tsumura M, Okada S, Miki M, Nakamura K, Kunishima S, Inaba T, Kobayashi M.	Identification of the integrin $\beta 3$ L718P mutation in a pedigree with autosomal dominant thrombocytopenia with anisocytosis.	Br J Haematol	in press		2012
Tsumura M, Okada S, Sakai H, Yasunaga S, Ohtsubo M, Murata T, Obata H, Yasumi T, Kong XF, Abhyankar A, Heike T, Nakahata T, Nishikomori R, Al-Muhsen S, Boisson-Dupuis S, Casanova JL, Alzahrani M, Shehri MA, Elghazali G, Takihara Y, Kobayashi M.	Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease.	Human Mutation	33(9)	1377-87	2012
Zhang X, Inukai T, Hirose K, Akahane K, Kuroda I, Honna-Oshiro H, Kagami K, Goi K, Nakamura K, Kobayashi M, Endo M, Yagita H, Kurosawa H, Thomas Look A, Honda H, Inaba T, Nakazawa S, Sugita K.	Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.	Leukemia.	26(12)	2483-93	2012
Ohno N, Kobayashi M, Hayakawa S, Utsunomiya A, Karakawa S.	Transient pseudothrombocytopenia in a neonate: Transmission of a maternal EDTA-dependent anticoagulant.	Platelets	23(5)	399-400	2012
Kajiume T, Sera Y, Kawahara Y, Matsumoto M, Fukazawa T, Imura T, Yuge L, Kobayashi M.	Regulation of hematopoietic stem cells using protein transduction domain-fused Polycomb.	Exp Hematol.	40(9)	751-760	2012
Ichikawa M, Suzuki D, Inamoto J, Ohshima J, Cho Y, Saitoh S, Kaneda M, Iguchi A, Ariga T.	Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.	J Pediatr Hematol Oncol.	34	239-41	2012
Sarashina T, Yoshida M, Iguchi A, Okubo H, Toriumi N, Suzuki D, Sano H, Kobayashi R.	Risk factor analysis of bloodstream infection in pediatric patients after hematopoietic stem cell transplantation.	J Pediatr Hematol Oncol.	35	76-80	2013
Sato T, Okumura F, Iguchi A, Ariga T, Hatakeyama S.	TRIM32 promotes retinoic acid receptor $\alpha$ -mediated differentiation in human promyelogenous leukemic cell line HL60.	Biochem Biophys Res Commun.	417	594-600	2012
Takezaki S, Okura Y, Ichikawa M, Suzuki D, Ohshima J, Kaneda M, Cho Y, Yamada M, Kawamura N, Iguchi A, Kobayashi I, Ariga T.	Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab.	Mod Rheumatol.	22	621-4	2012
Okura Y, Nawate M, Takahashi Y, Kobayashi I, Yamada M, Ariga T.	Rheumatoid factor-positive synovitis in a patient with C3 deficiency.	Scand J Rheumatol.	41	405-6	2012
Cho Y, Iizuka S, Hatae Y, Kobayashi K, Hattori Y, Yamashiro Y, Ariga T.	A 25-year observation of a Japanese female patient with Hb Nottingham who has two children with the same disorder.	Hemoglobin.	36	446-55	2012
Shibata M, Sato T, Nukiwa R, Ariga T, Hatakeyama S.	TRIM45 negatively regulates NF- $\kappa$ B-mediated transcription and suppresses cell proliferation.	Biochem Biophys Res Commun.	423	104-9	2012
Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y.	Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.	Pediatr Blood Cancer.	59	499-505	2012
Koseki N, Teramoto S, Kaiho M, Gomi-Endo R, Yoshioka M, Takahashi Y, Nakayama T, Sawada H, Konno M, Ushijima H, Kikuta H, Ariga T, Ishiguro N.	Detection of human bocaviruses 1 to 4 from nasopharyngeal swab samples collected from patients with respiratory tract infections.	J Clin Microbiol.	50	2118-21	2012
Ariga T.	Wiskott-Aldrich syndrome: an x-linked primary immunodeficiency disease with unique and characteristic features.	Allergol Int.	61	183-9	2012
Sato T, Okumura F, Ariga T, Hatakeyama S.	TRIM6 interacts with Myc and maintains the pluripotency of mouse embryonic stem cells.	J Cell Sci.	125	1544-55	2012
Yamada M, Okura Y, Suzuki Y, Fukumura S, Miyazaki T, Ikeda H, Takezaki S, Kawamura N, Kobayashi I, Ariga T.	Somatic mosaicism in two unrelated patients with X-linked chronic granulomatous disease characterized by the presence of a small population of normal cells.	Gene.	497	110-5	2012
Morishima T, Nomura A, Saida S, Watanabe K, Yagi H, Matsumoto M, Fujimura Y, Heike T, Nakahata T, Adachi S.	Pediatric idiopathic TTP diagnosed with decreased ADAMTS13 activity.	Pediatr. Int.	54(3)	422-3	2012
Tsuchiya A, Imai M, Kamimura H, Takamura M, Yamagiwa S, Sugiyama T, Nomoto M, Heike T, Nagasawa T, Nakahata T, Aoyagi Y.	Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice.	Dig. Dis. Sci.	57(11)	2892-2900	2012
Kikuchi A, Hasegawa D, Ohtsuka Y, Hamamoto K, Kojima S, Okamura J, Nakahata T, Manabe A.	Outcome of children with Refractory Anaemia with Excess of Blast (RAEB) and RAEB in Transformation (RAEB-T) in the Japanese MDS99 study.	Brit. J. Haematol.	158(5)	657-661	2012
Nakazawa Y, Saito S, Yanagisawa R, Suzuki T, Toshiro Ito T, Ishida F, Muramatsu H, Matsumoto K, Kato K, Ishida H, Umeda K, Souichi Adachi S, Nakahata T, Koike K.	Recipient seropositivity for adenovirus type 11 is highly predictive of the development of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.	Bone Marrow Transplant.	in press		2012
Saida S, Watanabe K, Sato-Otsubo A, Terui K, Yoshida K, Okuno Y, Toki T, Wang RN, Shiraiishi Y, Miyano S, Kato I, Morishima T, Fujino H, Umeda K, Hiramatsu H, Adachi S, Ito E, Ogawa S, Ito M, Nakahata T, Heike T.	Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.	Blood	in press		2012

Kanegane H, Yang X, Zhao M, et al.	Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatric allergy and immunology.	Pediatr Allergy Immunol.	23(5)	488-93	2012
Marsh R. a. Rao, K, Satwani P, et al.	Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.	Blood	121(6)	877-83	2013
Yoshimi A, Kamachi Y, Imai K, Watanabe N, Nakadate H, Kanazawa T, Ozono S, Kobayashi R, Yoshida M, Kobayashi C, Hama A, Muramatsu H, Sasahara Y, Jakob M, Morio T, Ehl S, Manabe A, Niemeyer C, Kojima S.	Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia.	Pediatric blood & cancer	in press		2012
Shimada A, Takahashi Y, Muramatsu H, Hama A, Ismael O, Narita A, Sakaguchi H, Doisaki S, Nishio N, Tanaka M, Yoshida N, Matsumoto K, Kato K, Watanabe N, Kojima S.	Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen.	International journal of hematology	95	675-679	2012
Sakaguchi H, Takahashi Y, Watanabe N, Doisaki S, Muramatsu H, Hama A, Shimada A, Yagasaki H, Kudo K, Kojima S.	Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies.	Leukemia research	in press		2012
Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S.	Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.	Blood	120	1485-1488	2012
Wang X, Muramatsu H, Sakaguchi H, Xu Y, Narita A, Tsumura Y, Doisaki S, Tanaka M, Ismael O, Shimada A, Hama A, Takahashi Y, Kojima S.	Mutation in the THPO gene is not associated with aplastic anaemia in Japanese children.	British journal of haematology	158	553-555	2012
Sakaguchi H, Takahashi Y, Watanabe N, Doisaki S, Muramatsu H, Hama A, Shimada A, Yagasaki H, Kudo K, Kojima S.	Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in	Pediatric blood & cancer	58	780-784	2012
Saito Y, Aoki Y, Muramatsu H, Makishima H, Maciejewski JP, Imaizumi M, Rikiishi T, Sasahara Y, Kure S, Niihori T, Tsuchiya S, Kojima S, Matsubara Y.	Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.	Leukemia research	36	1009-1015	2012
Narita A, Muramatsu H, Takahashi Y, Sakaguchi H, Doisaki S, Nishio N, Hama A, Shimada A, Ito M, Kojima S.	Autoimmune-like hepatitis following unrelated BMT successfully treated with rituximab.	Bone marrow transplantation	47	600-602	2012
Muramatsu H, Makishima H, Maciejewski JP.	Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.	Seminars in oncology	39	67	2012
Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, O'Keefe C, Sauntharajah Y, Maciejewski JP.	CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.	Leukemia	26	1547-1554	2012
Kato K, Otake H, Tagaya M, Takahashi Y, Ito Y, Hama A, Muramatsu H, Kojima S, Naganawa S, Nakashima T.	Progressive hearing loss following acquired cytomegalovirus infection in an immunocompromised child.	American journal of otolaryngology	in press		2012
Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boulwood J, Mufti GJ, Maciejewski JP.	Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.	Blood	119	6109-6117	2012
Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N, Ito M, Takahashi Y, Akita N, Sunami S, Ohtsuka Y, Asada Y, Fujisaki H, Kojima S.	Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.	Pediatric blood & cancer	59	530-535	2012
Ismael O, Shimada A, Hama A, Elshazley M, Muramatsu H, Goto A, Sakaguchi H, Tanaka M, Takahashi Y, Yinyan X, Fukuda M, Miyajima Y, Yamashita Y, Horibe K, Hanada R, Ito M, Kojima S.	De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.	British journal of haematology	158	129-137	2012
Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, Maciejewski JP.	Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.	British journal of haematology	15	316-325	2012
Fukushima H, Fukushima T, Hiraki A, Suzuki R, Mahmoud SS, Yoshimi A, Nakao T, Kato K, Kobayashi C, Koike K, Fukasawa M, Morishita Y, Doisaki S, Muramatsu H, Sumazaki R.	Central nervous system lesions due to juvenile myelomonocytic leukemia progressed in a boy undergoing first line chemotherapy.	International journal of hematology	95	581-584	2012
Abu Kar S, Jankowska AM, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, Maciejewski JP.	Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.	Haematologica	in press		2012

Obinata K, Lee T, Niizuma T, Kinoshita K, Shimizu T, Hoshina T, Sasaki Y, Hara T.	Two cases of partial dominant interferon- $\gamma$ receptor 1 deficiency that presented with different clinical courses of bacille Calmette-Guérin multiple osteomyelitis.	J Infect Chemother.	in press		2012
Kusuhara K, Hoshina T, Saito M, Ishimura M, Inoue H, Horiuchi T, Sato T, Hara T.	Successful treatment of a patient with tumor necrosis factor receptor-associated periodic syndrome using a half-dose of etanercept.	Pediatr Int.	54	552-555	2012
Hoshina T, Kusuhara K, Saito M, Mizuno Y, Hara T.	NKRP1A+ $\gamma\delta$ and $\alpha\beta$ T cells are preferentially induced in patients with Salmonella infection.	Hum Immunol.	73	623-628	2012
Yamamura K, Ihara K, Ikeda K, Nagata H, Mizuno Y, Hara T.	Histo-blood group gene polymorphisms as potential genetic modifiers of the development of coronary artery lesions in patients with Kawasaki disease.	Int J Immunogenet.	39(2)	119-125	2012
Onoyama S, Ihara K, Yamaguchi Y, Ikeda K, Yamaguchi K, Yamamura K, Hoshina T, Mizuno Y, Hara T.	Genetic susceptibility to Kawasaki disease: analysis of pattern recognition receptor genes.	Hum Immunol.	73	654-660	2012
Yamamura K, Joo K, Ohga S, Nagata H, Ikeda K, Muneuchi J, Watanabe M, Hara T.	Thrombocytosis in asplenia syndrome with congenital heart disease: a previously unrecognized risk factor for thromboembolism.	Int J Cardiol.	in press		2012
Shiraishi A, Ohga S, Doi T, Ishimura M, Takimoto T, Takada H, Miyamoto T, Abe Y, Hara T.	Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.	Pediatr Blood Cancer.	59	265-270	2012
Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S.	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.	Clin Rheumatol.	31	1713-1721	2012
Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T.	Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.	Mod Rheumatol.	in press		2012
Kitajima J, Inoue H, Ohga S, Kinjo T, Ochiai M, Yoshida T, Kusuhara K, Hara T.	Differential transmission and postnatal outcome in triplets with congenital cytomegalovirus infection.	Pediatr Development Pathol.	15	151-155	2012
Kamae C, Nakagawa N, Sato H, Honma K, Mitsui N, Ohara O, Kanegane H, Pasic S, Pan-Hammarström Q, van Zelm MC, Morio T, Imai K, Nonoyama S.	Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin $\kappa$ -deleting recombination excision circles.	J Allergy Clin Immunol.	in press		2012
Kawasaki Y, Toyoda H, Otsuki S, Iwasa T, Iwamoto S, Azuma E, Itoh-Habe N, Wada H, Fujimura Y, Morio T, Imai K, Mitsui N, Ohara O, Komada Y.	A novel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura.	Eur J Haematol.	in press		2012
Kanegane H, H. Taneichi, K. Nomura, T. Wada, A. Yachie, K. Imai, T. Ariga, I. Santisteban, M.S. Hershfield, and T. Miyawaki.	Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.	Pediatr Transplant	in press		2012

雑誌

発表者名	論文タイトル名	発表雑誌	巻号	ページ	出版年
溝口 洋子, 鎌田 綾, 三木 瑞香, 谷 博雄, 世羅 康彦, 中村 和洋, 小林 正夫	Glanzmann thrombastheniaへの遺伝子組み換え活性型第VII因子製剤による止血効果	日本小児血液・がん学会雑誌	49(1-2)9	61-66	2012
梶梅 輝之, 浅野 孝基, 世羅 康彦, 小林 正夫	輸血後蕁麻疹発症前の末梢血一般検査所見	アレルギー	61(8)	1086-1091	2012
溝口洋子, 津村弥来, 岡田賢, 小林正夫	慢性性皮膚粘膜カンジダ症と機能獲得性STAT1変異	臨床免疫・アレルギー科	57(4)	437-443	2012
中畑龍俊	白血病治療の進歩と今後の展望	日本小児血液・がん学会雑誌	第49巻 1・2号		2012
中畑龍俊、丹羽明	幹細胞増幅、第10章 内科疾患と再生医療	カラー版内科学 門脇孝、永井良三(総編集)		447-450	2012
斎藤潤、中畑龍俊	疾患特異的iPS細胞	再生医療	12(1)	19-29	2013
今井 耕輔	原発性免疫不全症の最新国際分類.臨床免疫	アレルギー科	58	446-466	2012
今井耕輔	原発性免疫不全症の遺伝子診断・治療	臨床血液	53	1865-1873	2012
今井耕輔	特集 乳幼児健診Q&A VII.歯科 Q 口の中にミルクのかすのようなものがいつもありますが、大丈夫ですか	小児科診療	11	2045-2048	2012
今井耕輔	臨床検査の意義と限界 T細胞・B細胞サブセット	小児内科	44	645-648	2012
今井耕輔	【知っておきたい内科症候群】膠原病・免疫・アレルギー《免疫不全症》 ウィスコット・アルドリッチ症候群	内科	109	1501-1503	2012

## IV 研究成果の刊行に関する一覧 別冊



# blood

2012 119: 3997-4008  
Prepublished online March 8, 2012;  
doi:10.1182/blood-2011-11-392985

## **Functional STAT3 deficiency compromises the generation of human T follicular helper cells**

Cindy S. Ma, Danielle T. Avery, Anna Chan, Marcel Batten, Jacinta Bustamante, Stephanie Boisson-Dupuis, Peter D. Arkwright, Alexandra Y. Kreins, Diana Averbuch, Dan Engelhard, Klaus Magdorf, Sara S. Kilic, Yoshiyuki Minegishi, Shigeaki Nonoyama, Martyn A. French, Sharon Choo, Joanne M. Smart, Jane Peake, Melanie Wong, Paul Gray, Matthew C. Cook, David A. Fulcher, Jean-Laurent Casanova, Elissa K. Deenick and Stuart G. Tangye

---

Updated information and services can be found at:  
<http://bloodjournal.hematologylibrary.org/content/119/17/3997.full.html>

Articles on similar topics can be found in the following Blood collections  
Immunobiology (4924 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub\\_requests](http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.  
Copyright 2011 by The American Society of Hematology; all rights reserved.



# Functional STAT3 deficiency compromises the generation of human T follicular helper cells

Cindy S. Ma,<sup>1,2</sup> Danielle T. Avery,<sup>1</sup> Anna Chan,<sup>1</sup> Marcel Batten,<sup>1,2</sup> Jacinta Bustamante,<sup>3,4</sup> Stephanie Boisson-Dupuis,<sup>3,5</sup> Peter D. Arkwright,<sup>6</sup> Alexandra Y. Kreins,<sup>5</sup> Diana Averbuch,<sup>7</sup> Dan Engelhard,<sup>7</sup> Klaus Magdorf,<sup>8</sup> Sara S. Kilic,<sup>9</sup> Yoshiyuki Minegishi,<sup>10</sup> Shigeaki Nonoyama,<sup>11</sup> Martyn A. French,<sup>12,13</sup> Sharon Choo,<sup>14</sup> Joanne M. Smart,<sup>14</sup> Jane Peake,<sup>15</sup> Melanie Wong,<sup>16</sup> Paul Gray,<sup>17</sup> Matthew C. Cook,<sup>18-20</sup> David A. Fulcher,<sup>21</sup> Jean-Laurent Casanova,<sup>3,5</sup> Elissa K. Deenick,<sup>1,2</sup> and Stuart G. Tangye<sup>1,2</sup>

<sup>1</sup>Immunology Research Program, Garvan Institute of Medical Research, Darlinghurst, Australia; <sup>2</sup>St Vincent's Clinical School, University of New South Wales, Sydney, Australia; <sup>3</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U550, Necker Medical School, Université Paris Descartes, Paris, France; <sup>4</sup>Center for the Study of Primary Immunodeficiencies, Assistance Publique des Hôpitaux de Paris (AP-HP), Necker Hospital, Paris, France; <sup>5</sup>Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; <sup>6</sup>University of Manchester, Royal Manchester Children's Hospital, Manchester, United Kingdom; <sup>7</sup>Department of Pediatrics and Pediatric Infectious Diseases, Hadassah-Hebrew University Medical Centre, Ein-Kerem, Jerusalem, Israel; <sup>8</sup>Department of Pediatric Pneumology and Immunology, Charité, Humboldt University of Berlin, Berlin, Germany; <sup>9</sup>Department of Pediatrics, Uludag University School of Medicine, Bursa, Turkey; <sup>10</sup>Department of Immune Regulation, Tokyo Medical and Dental University Graduate School, Tokyo, Japan; <sup>11</sup>Department of Pediatrics, National Defense Medical College, Saitama, Japan; <sup>12</sup>Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia; <sup>13</sup>School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; <sup>14</sup>Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia; <sup>15</sup>Department of Paediatrics and Child Health, Royal Children's Hospital Brisbane, Brisbane, Australia; <sup>16</sup>Department of Immunology, Children's Hospital at Westmead, Australia; <sup>17</sup>University of New South Wales School of Women's and Children's Health, NSW, Australia; <sup>18</sup>Australian National University Medical School, Australian National University, Canberra, Australia; <sup>19</sup>John Curtin School of Medical Research, Australian National University, Canberra, Australia; <sup>20</sup>Department of Immunology, The Canberra Hospital, Canberra, Australia; and <sup>21</sup>Department of Immunology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia

T follicular helper (Tfh) cells are critical for providing the necessary signals to induce differentiation of B cells into memory and Ab-secreting cells. Accordingly, it is important to identify the molecular requirements for Tfh cell development and function. We previously found that IL-12 mediates the differentiation of human CD4<sup>+</sup> T cells to the Tfh lineage, because IL-12 induces naive human CD4<sup>+</sup> T cells to acquire expression of IL-21, BCL6, ICOS, and CXCR5, which

typify Tfh cells. We have now examined CD4<sup>+</sup> T cells from patients deficient in IL-12Rβ1, TYK2, STAT1, and STAT3 to further explore the pathways involved in human Tfh cell differentiation. Although STAT1 was dispensable, mutations in *IL12RB1*, *TYK2*, or *STAT3* compromised IL-12-induced expression of IL-21 by human CD4<sup>+</sup> T cells. Defective expression of IL-21 by STAT3-deficient CD4<sup>+</sup> T cells resulted in diminished B-cell helper activity in vitro. Importantly, muta-

tions in *STAT3*, but not *IL12RB1* or *TYK2*, also reduced Tfh cell generation in vivo, evidenced by decreased circulating CD4<sup>+</sup>CXCR5<sup>+</sup> T cells. These results highlight the nonredundant role of STAT3 in human Tfh cell differentiation and suggest that defective Tfh cell development and/or function contributes to the humoral defects observed in STAT3-deficient patients. (*Blood*. 2012;119(17):3997-4008)

## Introduction

The generation of robust Ab responses is crucial for the correct functioning of the immune system. The importance of this is apparent in diseases that result from dysregulated humoral immune responses. For example, immunodeficient states and autoimmune disorders can develop as a consequence of impaired or exaggerated Ab responses, respectively. Thus, it is imperative to identify factors that control Ab responses. Early studies found that T cells play an important role in initiating Ab responses (reviewed in Tangye et al<sup>1</sup>). This was mediated by instructive signals in the form of cell-cell contacts and secretion of soluble mediators such as cytokines. More recently, a subset of CD4<sup>+</sup> T cells with specialized B-cell helper capabilities was identified that is now referred to as T follicular helper (Tfh) cells.<sup>2,3</sup> Tfh cells are identified by several characteristics that also serve functional roles. Thus, Tfh cells express the chemokine receptor CXCR5,<sup>2,3</sup> which facilitates their

positioning to B-cell follicles in secondary lymphoid tissues, and the transcription factor Bcl-6,<sup>4</sup> which is required for the commitment of naive CD4<sup>+</sup> T cells to the Tfh lineage.<sup>5-7</sup> Tfh cells also express the costimulatory molecules CD40L, ICOS, OX40, and members of the SLAM family, as well as the cytokine IL-21,<sup>2-4,8-12</sup> all of which play important roles in the induction of T cell-dependent (TD) B-cell activation and differentiation.

Because of the importance of Tfh cells in regulating Ab responses, much work has been performed to determine the requirements for their differentiation from naive CD4<sup>+</sup> T cells. It was initially found that IL-21 was required for the development of murine Tfh cells.<sup>13,14</sup> This was later expanded to include IL-6 and IL-27.<sup>15-17</sup> However, conflicting findings have been made about the relative importance of IL-6 and IL-21 to murine Tfh cell formation<sup>18,19</sup>; this may reflect redundancy because these cytokines, as

Submitted November 22, 2011; accepted February 28, 2012. Prepublished online as *Blood* First Edition paper, March 8, 2012; DOI 10.1182/blood-2011-11-392985.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology

**Table 1. Primary immunodeficient patients**

Disease	Patient ID	Mutation/genotype	
MSMD (IL-12Rβ1 deficiency)	IL12RB1#1	1745_1746insCA+1483 + 182-1619-1073del	
	IL12RB1#2	628_644dup	
	IL12RB1#3	R173P	
	IL12RB1#4	1791 + 2T > G	
	IL12RB1#5	C198R	
	IL12RB1#6	1623_1624delinsTT	
MSMD + viral infection (STAT1 deficiency)	STAT1#1	1928insA (homozygous)	
	STAT1#2	P696S (homozygous)	
	STAT1#3	P696S (homozygous)	
MSMD only (STAT1 deficiency)	STAT1#4	Q463H/WT	
	STAT1#5	L706S/WT	
	STAT1#6	L706S/WT	
AD-CMC	STAT1gof#1	A267V	
	STAT1gof#2	A267V	
	STAT1gof#3	A267V	
AD-HIES	STAT3#1	R382Q	
	STAT3#2	V637M	
	STAT3#3	R382Q	
	STAT3#4	H437P	
	STAT3#5	Q644P	
	STAT3#6	S465F	
	STAT3#7	Y657N	
	STAT3#8	R382W	
	STAT3#9	L706M	
	STAT3#10	L706M	
	STAT3#13	V463del	
	STAT3#14	V463del	
	STAT3#15	R593P	
	STAT3#16	V463del	
	AR-HIES (incl infection with mycobacteria, viruses and fungi)	TYK2#1	550_553GCTTdel (homozygous)
	MSMD + viral infection	TYK2#2	2292-2301del

MSMD indicates Mendelian susceptibility to mycobacterial disease; WT, wild type; AD-CMC, autosomal dominant chronic mucocutaneous candidiasis; AD-HIES, autosomal dominant hyper-IgE syndrome; AR-HIES, autosomal recessive hyper-IgE syndrome; and gof, gain-of-function

well as IL-27, can operate through STAT3.<sup>20,21</sup> We and others previously showed that IL-12 is the key cytokine implicated in the differentiation of human Tfh cells in vitro.<sup>11,22</sup> IL-6, IL-21, IL-23, and IL-27 also induce human Tfh-like cells in vitro, albeit to a much lesser extent than IL-12.<sup>11,17,22</sup> We have now extended these observations by investigating the molecular requirements for the differentiation of naive human CD4<sup>+</sup> T cells into Tfh cells. This was achieved by studying patients with primary immunodeficiencies resulting from mutations in *IL12RB1*, *STAT1*, *STAT3*, and *TYK2*. IL-12-mediated induction of human Tfh-like cells was abolished in the absence of IL-12Rβ1 or TYK2, and significantly reduced in CD4<sup>+</sup> T cells deficient in STAT3 function. In contrast to the effects of IL-12, induction of Tfh cells by IL-6, IL-21, IL-23, and IL-27 was completely dependent on STAT3. These studies indicate that multiple cytokine pathways are involved in the differentiation of human Tfh cells, and IL-12 most efficiently induces human Tfh cells predominantly in a STAT3-dependent manner. This defect in generating Tfh cells from STAT3 mutant (STAT3<sub>MUT</sub>) CD4<sup>+</sup> T cells would contribute to impaired TD humoral immune responses observed in patients with *STAT3* mutations. In contrast, the ability of non-IL-12 cytokines to induce Tfh cell function is sufficient to elicit intact Ab responses in persons with impaired IL-12R signaling.

## Methods

### Human patient samples

Patients with mutations in *IL12RB1*, *STAT1*, *TYK2*, and *STAT3* have been previously described (Table 1<sup>23-28</sup>). PBMCs were isolated from these patients and healthy donors (Australian Red Cross). Tonsils were obtained from St Vincent's Hospital, Sydney. All studies were approved by Institutional Human Research Ethics Committees, and all participants gave written informed consent in accordance with the Declaration of Helsinki.

### Antibodies

Alexa-647-conjugated anti-IL-21, biotinylated anti-ICOS, PE-anti-CD4, Pacific Blue-anti-CD4, peridinin chlorophyll protein complex (PerCP)/cyanine 5.5-anti-CD45RA, anti-IFNγ, and FITC-anti-CD45RA were purchased from eBiosciences. Alexa-647-anti-CXCR5, allophycocyanin-anti-CD38, FITC-anti-CD20, PE-anti-CD4, anti-CD27, PerCP-anti-CD3 mAb, and streptavidin-PerCP were purchased from Becton Dickinson. Allophycocyanin-anti-CD4 was purchased from Caltag, and FITC-anti-CCR7 was purchased from R&D Systems.

### CD4<sup>+</sup> T-cell isolation

CD4<sup>+</sup> T cells were isolated from healthy donors or immunodeficient patients with the use of Dynal beads.<sup>23</sup> Peripheral blood (PB) CD4<sup>+</sup> T cells were labeled with anti-CD4, anti-CD45RA, and anti-CCR7, and naive

**Table 2. Primers for qPCR**

Gene	Primers	UPL probe	Amplicon size, bp
<i>BCL6</i>	fwd: gagctctgttgattcttagaactgg rev: gccttgcttcacagtccaa	9	110
<i>TBX21</i>	fwd: tgttggtccaagttaatcagca	9	77
<i>IL21</i>	rev: tgacaggaatggaacatcc fwd: aggaaaccacctccacaaa rev: gaatcacatgaaggcatgtt	7	68
<i>IFNG</i>	fwd: ggcattttgaagaattgaaaag rev: ttggatgctctggtcatctt	21	112
<i>GAPDH</i>	fwd: ctctgctcctctgttcgac rev: acgacaaaatccgtgact	60	112

CD45RA<sup>+</sup>CCR7<sup>+</sup> CD4<sup>+</sup> T cells were isolated (> 98% purity) with the use of a FACSAria (BD Biosciences).

### Cell cultures

Naive PB CD4<sup>+</sup> T cells were labeled with CFSE (Molecular Probes) and cultured with T-cell activation and expansion beads (anti-CD2/CD3/CD28; Miltenyi Biotec) alone (nil culture) or under Th1 (IL-12 [20 ng/ml; R&D systems]), Th2 (IL-4 [100 U/ml]), or Th17 (IL-1β [20 ng/ml; Peprotech]), IL-6 (50 ng/ml; PeproTech), IL-21 (50 ng/ml; PeproTech), IL-23 (20 ng/ml; eBioscience), anti-IL-4 (5 μg/ml), and anti-IFNγ (5 μg/ml; eBioscience)<sup>23,29</sup> polarizing conditions, or with IL-6, IL-21, IL-23, or IL-27 (50 ng/ml; eBioscience) alone. After 4 or 5 days, expression of intracellular cytokines, transcription factors, and surface phenotype of cells determined.

### T- and B-cell coculture assays

Naive CD4<sup>+</sup> T cells were activated for 5 days (see previous section), treated with mitomycin C (100 μg/ml; Sigma-Aldrich) and then cocultured at a 1:1 ratio (50 × 10<sup>3</sup>/200 μL/well) with sort-purified allogeneic naive (CD20<sup>+</sup>CD27<sup>-</sup>CD38<sup>inter</sup>) tonsillar B cells.<sup>11,29</sup> After 7 days Ig secretion was determined by ELISA.<sup>29</sup>

### Cytokine and transcription factor expressions

Activated CD4<sup>+</sup> T cells were restimulated with phorbol 12-myristate 13-acetate (100 ng/ml) and ionomycin (750 ng/ml) for 6 hours, with Brefeldin A (10 μg/ml) added after 2 hours. Cells were then fixed with formaldehyde, and expression of cytokines was detected by intracellular staining.<sup>23,29</sup> RNA was extracted with the use of RNeasy kit (QIAGEN) and transcribed into cDNA with the use of random hexamers and Superscript III (Invitrogen). All quantitative PCR (qPCR) primers (Integrated DNA Technologies) were designed with Roche UPL Primer Design Program. Primer sequences, Roche UPL probes, and size of each amplicon are listed in Table 2. qPCR was performed with Roche LightCycler 480 Probe Master Mix and Roche Lightcycler 480 System with the following conditions: denaturation at 95°C for 10 minutes; amplification for 45 cycles at 95°C for 10 seconds, 65°C for 30 seconds, and 72°C for 5 seconds; and cooling at 40°C for 30 seconds. All reactions were standardized to *GAPDH*.

## Results


### Patients deficient for IL-12Rβ1 have altered differentiation of CD4<sup>+</sup> T cells in vivo

IL-12 can induce human naive CD4<sup>+</sup> T cells to differentiate into IL-21-expressing cells that resemble T<sub>H</sub> cells in vitro.<sup>11,22</sup> To investigate this function of IL-12 further, we examined patients with homozygous or compound heterozygous null mutations in *IL12RB1*.<sup>26</sup> We first determined the frequency of total CD4<sup>+</sup> T cells and CD4<sup>+</sup> T cells with a naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>-</sup>CCR7<sup>+</sup>), or T<sub>H</sub> (CXCR5<sup>+</sup>) phenotype in healthy

donors (age range, 16-64 years) and patients deficient for IL-12Rβ1 (Figure 1A-D,F). Patients deficient for IL-12Rβ1 had a normal frequency of CD4<sup>+</sup> T cells (Figure 1; Table 3). In contrast, they had a significant increase in the frequency of naive and a corresponding significant decrease in memory CD4<sup>+</sup> T cells (Figure 1A-E; Table 3). When the phenotype of CXCR5<sup>+</sup> T cells was analyzed, ~90% were found within the CD45RA<sup>-</sup> (ie, memory) subset (Table 3<sup>2,3,11</sup>). Therefore, we analyzed the frequency of both CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> T cells in healthy donors and in patients deficient for IL-12Rβ1. No significant difference was observed for the frequency of circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> or CD45RA<sup>+</sup> T<sub>H</sub>-like cells in healthy donors and patients deficient for IL-12Rβ1 (Figure 1A-B,F; Table 3).

### Naive CD4<sup>+</sup> T cells from patients deficient for IL-12Rβ1 are unable to differentiate into IL-21-expressing cells in response to IL-12

To assess the potential of CD4<sup>+</sup> T cells deficient for IL-12Rβ1 to differentiate into T<sub>H</sub>-like cells, we examined the ability of naive cells to express IL-21 in vitro. Naive CD4<sup>+</sup> T cells were cultured with T-cell activation and expansion beads alone (nil) or with IL-12 (Th1). After 5 days, cells were restimulated with phorbol 12-myristate 13-acetate/ionomycin, and the expression of IL-21 and IFNγ was then determined. Naive CD4<sup>+</sup> T cells from either healthy donors or patients deficient for IL-12Rβ1 expressed little IL-21 or IFNγ when cultured under neutral (nil) conditions (Figure 1G-J). However, when normal naive CD4<sup>+</sup> T cells were cultured under Th1-polarizing conditions (ie, with IL-12), IL-21- and IFNγ-expressing cells were readily detectable (Figure 1G,I,J). In contrast, IL-12 failed to induce IL-21 or IFNγ in naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1 (Figure 1H-J). Next, we questioned whether naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1 could differentiate into IL-21-expressing cells in response to other cytokines and signaling pathways. Accordingly, naive CD4<sup>+</sup> T cells from healthy donors and patients deficient for IL-12Rβ1 were subjected to Th2 (IL-4) and Th17 (IL-1β, IL-6, IL-21, IL-23) polarizing conditions or were cultured in the presence of IL-6, IL-21, IL-23, or IL-27. A small frequency of IL-21-expressing cells could be generated from both normal and IL-12Rβ1-deficient naive CD4<sup>+</sup> T cells activated with IL-21 or IL-27 (Figure 1I). Similarly, although IL-12 could not induce IFNγ in naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1, the ability of IL-27 to induce IFNγ was unaffected by *IL12RB1* mutations (Figure 1J). Taken together these results indicate that, although IL-12-induced IL-21 expression is abrogated by *IL12RB1* mutations, other cytokines and their associated signaling pathways that induce IL-21 (eg, IL-21 and IL-27, albeit to a lesser extent than IL-12) are intact, which is consistent with normal Ab responses to infection and vaccinations in these patients.<sup>30,31</sup>



**Figure 1. Naive CD4<sup>+</sup> T cells deficient for IL-12R $\beta$ 1 fail to differentiate into IL-21-expressing cells in response to IL-12.** (A-F) The frequency of total CD4<sup>+</sup> T cells, and naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), and memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, in PBMCs was determined for healthy donors and patients deficient for IL-12R $\beta$ 1. (A-B) Representative dot plots from 1 donor and 1 patient. (C-F) The frequency of (C) total, (D) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (E) memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and (F) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and patients deficient for IL-12R $\beta$ 1 examined (n = 6). (G-J) Naive CD4<sup>+</sup> T cells isolated from healthy donors (n = 5) and patients deficient for IL-12R $\beta$ 1 (n = 5) were cultured for 5 days under neutral (nil); polarizing Th1, Th2, or Th17 conditions; or in the presence of IL-6, IL-21, IL-23, or IL-27, and intracellular expression of IL-21 and IFN $\gamma$  were then determined. (G-H) Representative dot plots of IL-21 and IFN $\gamma$  expression by activated naive CD4<sup>+</sup> T cells from 1 donor and 1 patient deficient for IL-12R $\beta$ 1. (I-J) Percentage of activated normal and IL-12R $\beta$ 1-deficient naive CD4<sup>+</sup> T cells induced to express (I) IL-21 or (J) IFN $\gamma$  in response to the indicated culture. The values represent the mean  $\pm$  SEM.

**Analysis of cytokine responsiveness in STAT-deficient human CD4<sup>+</sup> T cells**

The cytokines that induce IL-21 in human naive CD4<sup>+</sup> T cells (IL-12, IL-6, IL-21, IL-23, IL-27)<sup>11,22</sup> function by activating

JAK/STAT signaling pathways. These cytokines phosphorylate STAT1 (IL-6, IL-12, IL-21, IL-23, IL-27), STAT3 (IL-6, IL-12, IL-21, IL-23, IL-27), STAT4 (IL-12, IL-23), and STAT5 (IL-12).<sup>20,21,24,32-35</sup> We confirmed these studies by showing that these

**Table 3. CD4<sup>+</sup> T-cell subsets in primary immunodeficiencies**

PID	CD4 <sup>+</sup> T cells	Naive CD4 <sup>+</sup> T cells	Memory CD4 <sup>+</sup> T cells	CXCR5 <sup>+</sup> CD45RA <sup>+</sup> CD4 <sup>+</sup> T cells	CXCR5 <sup>+</sup> CD45RA <sup>-</sup> CD4 <sup>+</sup> T cells
IL12RB1 (n = 6)	40 ± 4.4	71 ± 4.7	28 ± 4.7	1.6 ± 0.46	14 ± 2.8
STAT1 (n = 6)	40*	41 ± 10	56 ± 10	3.9 ± 0.68	11 ± 2.3
STAT3 (n = 14)	41 ± 3.1	65 ± 3.8	33 ± 3.7	1.5 ± 0.29 (n = 11)	8.7 ± 1.6 (n = 11)
TYK2 (n = 2)	41*	53 ± 24	43 ± 27	2.8 ± 1.2	15 ± 5.4
Controls	43 ± 1.4 (n = 54)	39 ± 1.7 (n = 70)	59 ± 1.7 (n = 70)	2.8 ± 0.24 (n = 61)	15 ± 1.1 (n = 61)

Values are mean ± SEM percentage.  
 PID indicates primary immunodeficiency.  
 \*Analysis was only performed on 1 patient.

IL-12–inducing cytokines predominantly activate STAT1, STAT3, and STAT4 in human naive CD4<sup>+</sup> T cells (data not shown), suggesting that these transcription factors are important in inducing Tfh cells in humans. To investigate this further, we took advantage of additional primary immunodeficiencies that result from mutations in components of several cytokine-signaling pathways, namely *STAT1*, *TYK2*, and *STAT3*.

**STAT1 is dispensable for IL-12–induced expression of IL-21 in human CD4<sup>+</sup> T cells**

STAT1-deficient patients and healthy donors had comparable frequencies of naive and memory CD4<sup>+</sup> T cells (Figure 2A-D; Table 3). The proportions of CXCR5<sup>+</sup>CD45RA<sup>-</sup> or CD45RA<sup>+</sup> Tfh cells in STAT1-deficient patients were also comparable with healthy donors (Figure 2A-B,E; Table 3). The ability of STAT1-deficient CD4<sup>+</sup> T cells to differentiate into IL-21<sup>+</sup> cells in response to Th1-polarizing conditions was then tested. Because of the limited numbers of cells available from these rare patients, total CD4<sup>+</sup> T cells were examined. When CD4<sup>+</sup> T cells from healthy donors or STAT1-deficient patients were activated under neutral conditions, IL-21 and IFN $\gamma$  production could be detected; however, the frequencies of cytokine-expressing cells was lower in STAT1-deficient patients (Figure 2F,H; IL-21: normal, 9.1% ± 6.2%; STAT1, 2.7% ± 1.8%; IFN $\gamma$ : normal, 11.3% ± 3.8%; STAT1, 1.6% ± 0.9%). Despite these differences in the nonpolarizing cultures, expression of IL-21 and IFN $\gamma$  in both normal and STAT1-deficient CD4<sup>+</sup> T cells increased after culture with IL-12 (Figure 2F,H; IL-21: normal, 30.5% ± 7.9%; STAT1, 13.2% ± 6.7%; IFN $\gamma$ : normal, 31.3% ± 7.9%; STAT1, 12.3% ± 2.5%). Although there appeared to be a reduced ability of IL-12 to enhance expression of IL-21 and IFN $\gamma$  in the absence of STAT1, compared with normal CD4<sup>+</sup> T cells (Figure 2F,H), when the effect of IL-12 was expressed as fold-change relative to nonpolarizing cultures, STAT1-deficient CD4<sup>+</sup> T cells responded comparably to normal cells, that is, ~ 4- to 6-fold increase in IL-21 (Figure 2G) and ~ 3- to 6-fold induction in IFN $\gamma$  expression (Figure 2I). Together these results indicate that IL-12–induced IL-21 and IFN $\gamma$  in CD4<sup>+</sup> T cells is independent of STAT1 signaling.


**Mutations in *STAT3* compromise the generation of CD4<sup>+</sup> memory and CXCR5<sup>+</sup> Tfh cells**

To investigate further the signaling pathways involved in the differentiation of IL-21–expressing cells we used patients with autosomal-dominant hyper IgE syndrome resulting from heterozygous mutations in *STAT3*.<sup>36,37</sup> Patients heterozygous for these mutations display impaired, but not abolished, STAT3 function with ~ 25% residual signaling.<sup>36,37</sup> As detailed above, STAT3 is activated by many cytokines, including those that induce IL-21

expression in human CD4<sup>+</sup> T cells (ie, IL-6, IL-12, IL-21, IL-23, IL-27).<sup>20,21,24,32-35</sup> The frequency of total CD4<sup>+</sup> T cells was comparable between healthy donors and STAT3<sup>MUT</sup> patients (Figure 3C). Compared with healthy donors, STAT3<sup>MUT</sup> patients have a significant increase in the frequency of naive and a significant decrease in the frequency of memory CD4<sup>+</sup> T cells (Figure 3A-F; Table 3). Analysis of CXCR5<sup>+</sup> T cells within the CD45RA<sup>+</sup> and CD45RA<sup>-</sup> fractions revealed significant decreases in both of these compartments in STAT3<sup>MUT</sup> patients compared with healthy donors (Figure 3A-B,F; Table 3). Thus, mutations in *STAT3* cause a ~ 50% reduction in the frequency of circulating CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> Tfh cells (Figure 3F; Table 3).

***STAT3* mutations partially impairs IL-12–induced expression of IL-21 in naive CD4<sup>+</sup> T cells**

The observations that (1) IL-12 is the main driver of human Tfh cell differentiation in vitro,<sup>11,22</sup> (2) IL-12 is capable of activating STAT3,<sup>21,32-35</sup> and (3) STAT3<sup>MUT</sup> patients have a contracted population of circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> Tfh-like cells (Figure 3E) led us to investigate the consequences of *STAT3* mutations on the ability of IL-12 to induce IL-21 in human naive CD4<sup>+</sup> T cells. No differences were observed in the low frequencies of IL-21– and IFN $\gamma$ –expressing cells detected in cultures of naive CD4<sup>+</sup> T cells from healthy donors or STAT3<sup>MUT</sup> patients after stimulation under neutral conditions (Figure 4A-D). However, induction of IL-21 expression by IL-12 was significantly reduced in STAT3<sup>MUT</sup> naive CD4<sup>+</sup> T cells compared with normal naive CD4<sup>+</sup> T cells (Figure 4A-C; normal, 20.9% ± 4.5%; STAT3<sup>MUT</sup>, 5.2% ± 1.3%). In fact this defect was most pronounced when the frequency of IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup> cells were determined (Figure 4A-B). This analysis found a significant (*P* < .01) decrease in IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup> cells but not IL-21<sup>+</sup>IFN $\gamma$ <sup>+</sup> (*P* > .05) cells in STAT3<sup>MUT</sup> patients compared with healthy donors after Th1 polarization (IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup>: normal, 16.7% ± 3.2%; STAT3<sup>MUT</sup>, 2.3% ± 0.5%; IL-21<sup>+</sup>IFN $\gamma$ <sup>+</sup>: normal, 4.8% ± 1.5%; STAT3<sup>MUT</sup>, 3.3% ± 1%). In contrast to IL-21, expression of IFN $\gamma$  in CD4<sup>+</sup> T cells in response to IL-12 was unaffected by *STAT3* mutations; in fact it was higher than normal CD4<sup>+</sup> T cells (Figure 4D). This increase in IFN $\gamma$  production by STAT3<sup>MUT</sup> CD4<sup>+</sup> T cells, however, did not contribute to decreased IL-21 production because neutralizing IFN $\gamma$  in these cultures had no effect on IL-21 expression, and there was a positive correlation between IL-21 and IFN $\gamma$  expression in both normal and STAT3<sup>MUT</sup> naive CD4<sup>+</sup> T cells after Th1 polarization (data not shown). It was possible that induction of IL-21 by IL-12 resulted from not only a direct effect of IL-12 but also the effects of other cytokines induced by IL-12 that act in an autocrine manner to further promote IL-21 expression. To address this, we examined IL-21 and IFN $\gamma$  expression in normal and STAT3<sup>MUT</sup> CD4<sup>+</sup> T cells by qPCR after 24 and 48 hours of




**Figure 2. STAT1 is dispensable for IL-12–induced expression of IL-21 in human CD4<sup>+</sup> T cells.** (A–E) The frequency of naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells in PBMCs was determined for healthy donors and STAT1-deficient patients. (A–B) Representative dot plots from 1 donor and 1 STAT1-deficient patient. (C–E) The frequency of (C) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (D) memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and (E) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and STAT1-deficient patients (n = 6) was examined. (F–I) Total CD4<sup>+</sup> T cells isolated from healthy donors and STAT1-deficient patients (n = 3) were cultured for 5 days under neutral (nil) or Th1-polarizing (ie, IL-12) conditions, and expression of intracellular IL-21 (F–G) and IFN $\gamma$  (H–I) was then determined. The graphs in panels F and H show the frequency of cytokine-positive cells; those in panels G and I depict cytokine expression after Th1 polarization as fold-increase relative to the nil culture in each experiment. The values represent the mean  $\pm$  SEM (n = 3).

stimulation with or without IL-12. Expression of *IL21* was substantially increased by IL-12 in normal CD4<sup>+</sup> T cells within 24 hours of stimulation, compared with cells cultured under neutral (nil) conditions, and similar levels were detected after 48 hours (supplemental Figure 1A–B, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Consistent with the flow cytometric analysis, expression of *IL21* in IL-12–activated STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells was reduced compared with normal controls (supplemental Figure 1A–B). In contrast to *IL21*, *IFNG* was abundantly expressed by IL-12–treated STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells; in fact, consistent with the intracellular staining data, *IFNG* expression by these cells exceeded that of normal naive CD4<sup>+</sup> T cells at the 48-hour time point

(supplemental Figure 1C–D). These data suggest that IL-12 acts directly to rapidly induce IL-21 expression in naive CD4<sup>+</sup> T cells.

IL-12 is capable of activating the JAK family protein tyrosine kinase TYK2,<sup>38</sup> which subsequently phosphorylates STATs, including STAT3.<sup>39</sup> Mutations in *TYK2* have been reported in 2 patients who developed susceptibility to various pathogens, including mycobacteria/Bacille Calmette-Guérin and herpes viruses.<sup>25,28</sup> One of the contributing factors to disease pathogenesis is believed to be the unresponsiveness of their T cells to IL-12 with respect to induction of IFN $\gamma$  expression.<sup>25</sup> To investigate this further, these 2 patients deficient for TYK2 were examined (supplemental Figure 2). CXCR5<sup>+</sup>CD45RA<sup>-</sup> Tfh-like cells were detected in both patients at similar frequencies as healthy donors (supplemental Figure 2A–B,E; Table 3). When IL-21 expression in total



**Figure 3. Mutations in *STAT3* compromise the generation of CD4<sup>+</sup> memory and CXCR5<sup>+</sup>CD45RA<sup>-</sup> Tfh cells.** (A-B) The frequency of naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>+</sup>CCR7<sup>-/-</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells in PBMCs was determined for healthy donors and STAT3<sub>MUT</sub> patients. (A-B) Representative dot plots from 1 donor and 1 patient. (C-F) The frequency of (C) total CD4<sup>+</sup> T cells, (D) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (E) memory (CD45RA<sup>+</sup>CCR7<sup>-/-</sup>), and (F) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and STAT3<sub>MUT</sub> patients (n = 14) was examined.

CD4<sup>+</sup> T cells from 1 patient deficient for *TYK2* after culture with IL-12 was examined, the level of induction was ~2-fold less than that observed for normal CD4<sup>+</sup> T cells (supplemental Figure 2F-G). We extended these studies by examining naive CD4<sup>+</sup> T cells from the second patient deficient for *TYK2*. Compared with normal naive CD4<sup>+</sup> T cells, induction of IL-21 expression by IL-12 in *TYK2*-deficient CD4<sup>+</sup> T cells was severely reduced (supplemental Figure 2I). Induction of IFN $\gamma$  was also dramatically compromised by *TYK2* mutations (supplemental Figure 2H,J). Taken together, these data suggest that mutations in *TYK2* and *STAT3*, which are both activated downstream of the IL-12R,<sup>21,32-35,38,39</sup> cause a significant impairment in the ability of naive CD4<sup>+</sup> T cells to differentiate into IL-21-expressing cells in response to IL-12.

#### **STAT3 mutations impede division-linked differentiation of CD4<sup>+</sup> T cells into IL-21-expressing effector cells**

Because IL-12 can promote proliferation of human activated T cells,<sup>40</sup> and differentiation of CD4<sup>+</sup> T cells into cytokine-expressing cells is linked to cell division,<sup>29,41</sup> it was important to determine whether the reduction in expression of IL-21 in IL-12-stimulated STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells resulted from reduced cell division or reflected an intrinsic defect in the differentiation program of these cells.


To do this, we examined proliferation by labeling naive CD4<sup>+</sup> T cells with CFSE and tracked their division after in vitro stimulation by monitoring CFSE dilution. There was no difference in cell division between normal or STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells

activated under neutral conditions (Figure 4E). Similarly, IL-12 increased proliferation regardless of whether the naive CD4<sup>+</sup> T cells were derived from healthy donors or STAT3<sub>MUT</sub> patients (Figure 4E). When IL-21 expression was examined on a per division basis, we found that it increased in normal CD4<sup>+</sup> T cells after the first few divisions and then reached a maximum, being expressed in ~20%-30% of cells after 2-3 divisions (Figure 4F). Expression of IL-21 by STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells also modestly increased with division; however, the frequency of IL-21<sup>+</sup> cells in each division never exceeded 10% and thus was dramatically reduced compared with normal CD4<sup>+</sup> T cells (Figure 4F). These data establish that the defect in IL-12-induced IL-21 induction in the absence of functional STAT3 was not because of a difference in proliferation, but rather because of an inability to efficiently acquire IL-21 during Tfh cell differentiation. Notably, when IFN $\gamma$  expression was also analyzed on a per division basis, the frequency of cytokine-positive cells continued to increase with each cell division (Figure 4G). Furthermore, the heightened frequency of IFN $\gamma$ <sup>+</sup> cells observed in STAT3<sub>MUT</sub> compared with normal CD4<sup>+</sup> T cells at the population level (Figure 4D and supplemental Figure 1) was also detected for cells that had undergone different divisions (Figure 4G).

#### **IL-12 can induce additional characteristics of Tfh cells in STAT3 mutant CD4<sup>+</sup> T cells**

IL-12 not only promotes IL-21 expression in human naive CD4<sup>+</sup> T cells but also induces additional features of Tfh cells such as






**Figure 4. STAT3 mutations impair IL-12-induced expression of IL-21 in naive CD4<sup>+</sup> T cells.** (A-D) Naive CD4<sup>+</sup> T cells isolated from healthy donors (n = 8) and STAT3<sub>MUT</sub> patients (n = 9) were cultured for 5 days under neutral conditions (nil); polarizing Th1, Th2, or Th17 conditions; or in the presence of IL-6, IL-21, IL-23, or IL-27, after which time expression of intracellular IL-21 and IFN $\gamma$  was determined. (A-B) Representative dot plots of cytokine expression by activated naive CD4<sup>+</sup> T cells from 1 donor and 1 patient. (C-D) Percentage of activated normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells induced to express (C) IL-21 or (D) IFN $\gamma$  in response to the indicated culture. The values represent the mean  $\pm$  SEM. (E-F) Naive CD4<sup>+</sup> T cells isolated from healthy donors and STAT3<sub>MUT</sub> patients were labeled with CFSE and cultured with anti-CD2/CD3/CD28 Abs in the absence (nil) or presence of Th1 polarizing conditions (+IL-12). After 5 days cells were harvested, and (E) proliferation and expression of (F) IL-21 and (G) IFN $\gamma$  in cells that had undergone different divisions were then determined. (F-G) The values represent the mean  $\pm$  SEM (n = 3).

sustained expression of CXCR5 and ICOS, and a modest induction of the Tfh lineage restricted transcription factor *BCL6*.<sup>4,11</sup> We therefore wanted to explore whether the effects of IL-12 on these aspects of CD4<sup>+</sup> T-cell activation were also compromised by


**Figure 5. Induction of CXCR5, ICOS, and BCL6 by IL-12 in CD4<sup>+</sup> T cells is independent of STAT3.** (A-D) Naive CD4<sup>+</sup> T cells isolated from healthy donors and STAT3<sub>MUT</sub> patients were cultured with anti-CD2/CD3/CD28 Abs in the absence (nil) or presence of Th1-polarizing conditions (+IL-12). After 4 days the cells were harvested, and surface expression of CXCR5 and ICOS was determined by flow cytometry and of *TBX21* and *BCL6* by qPCR. (A,C) representative histogram plots from 1 healthy donor and 1 STAT3<sub>MUT</sub> patient. Expression of (B) CXCR5 (n = 3), (D) ICOS (n = 3), (E) *TBX21* (n = 4), and (F) *BCL6* (n = 5) after Th1 polarization is presented as fold-increase compared with the nil culture in each experiment. (B,D-F) The graphs represent the mean ± SEM of the indicated number of experiments.



mutations in *STAT3*. Compared with naive CD4<sup>+</sup> T cells activated under neutral conditions, elevated expression of the Tfh cell markers CXCR5 and ICOS was observed when either normal or STAT3<sub>MUT</sub> cells were activated in the presence of IL-12 (Figure 5 A,C). In fact, compared with cells cultured under neutral conditions, IL-12 up-regulated CXCR5 and ICOS expressions by 2- to 3-fold on both normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells (Figure 5 B,D). IL-12 also up-regulated *TBX21* (encoding T-bet) and *BCL6*, the transcription factors required to generate Th1 and Tfh cells, respectively, to a comparable extent in normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells (Figure 5 E,F). Thus, IL-12-mediated induction of CXCR5, ICOS, and *BCL6* in Tfh-like cells either only require the residual levels of functional STAT3 that are available in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells or are STAT3-independent resulting from IL-12-induced activation of STAT4.<sup>20,21,34,38</sup> This

latter scenario would underlie the normal induction of *TBX21* and IFN $\gamma$  in STAT3<sub>MUT</sub> Th1 cells.

Consistent with our previous findings,<sup>11</sup> most of the other culture conditions used in this study (ie, Th2- and Th17-polarizing conditions; exogenous IL-6, IL-21, IL-23) had no effect on expression of CXCR5 and ICOS on normal CD4<sup>+</sup> T cells above that observed for the nonpolarizing culture (supplemental Figure 3A-B). However, IL-27 did modestly enhance ICOS expression (supplemental Figure 3B) and induce *TBX21* in naive CD4<sup>+</sup> T cells (supplemental Figure 3C), and this was independent of STAT3. Interestingly, Th17 polarizing culture conditions induced the greatest levels of *BCL6* in naive CD4<sup>+</sup> T cells, and this was substantially reduced in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells (supplemental Figure 3D), reflecting the contribution of STAT3 to the combined signaling of IL-6, IL-21, and IL-23 through their respective receptors.



**Figure 6. STAT3-deficient cells show impaired Tfh cell function in vitro.** Naive CD4<sup>+</sup> T cells isolated from healthy donors (HD) and STAT3<sub>MUT</sub> patients (Pt) were cultured under neutral (nil) or Th1 polarizing conditions. After 5 days, the cells were harvested and treated with mitomycin C before being cocultured with allogeneic naive B cells, in the absence or presence of exogenous IL-21, for an additional 7 days. After this time secretion of IgM, IgG, and IgA was determined. (A-B) The data were derived from experiments that used naive CD4<sup>+</sup> T cells isolated from different STAT3<sub>MUT</sub> patients; (C) the data show the effect of exogenous IL-21 on the ability of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to provide B-cell help. Each graph represents the mean  $\pm$  SEM of triplicate cultures; similar results were obtained in 5 (A-B) and 2 (C) experiments.

#### Defective IL-21 production by STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells results in impaired Tfh cell function in vitro

We next questioned whether a reduction in IL-21 expression in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells would result in a detectable functional defect, such as a compromised ability of these cells to provide help to B cells. To investigate this, we established an in vitro B-cell helper assay in which naive CD4<sup>+</sup> T cells were isolated from healthy donors and STAT3<sub>MUT</sub> patients and activated under neutral or Th1-polarizing conditions. After 5 days, the CD4<sup>+</sup> T cells were harvested and cocultured with naive B cells for an additional 7 days, after which time Ig secretion was quantified. Normal naive CD4<sup>+</sup> T cells activated under Th1 conditions provided significantly more help to support Ig production by cocultured B cells than when these T cells were cultured under neutral conditions (Figure 6A-C). Although priming under Th1 conditions also increased the helper function of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells relative to those cultured under neutral conditions, it was significantly less than that of normal CD4<sup>+</sup> T cells (Figure 6A-C). This reduction in B-cell help by IL-12-stimulated STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells approximated their reduction in expression of IL-21 under these culture conditions (ie, ~50%-70%; compare Figures 4C and 6A-C), thereby suggesting that the impaired ability of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to adequately promote B-cell differentiation resulted from insufficient production of IL-21. Indeed, the reduced ability of IL-12-primed STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to provide help to B cells could be overcome when IL-21 was added to the cocultures (Figure 6C). Thus, functional STAT3 deficiency compromises the ability of IL-12 to induce IL-21, which is subsequently detrimental to the capacity of these CD4<sup>+</sup> T cells to mediate the differentiation of B cells into Ig-secreting cells.

#### STAT3 mutations abolish IL-21 expression in naive CD4<sup>+</sup> T cells induced by IL-6, IL-21, IL-23, and IL-27

As previously shown, other cytokines (IL-6, IL-21, IL-23, IL-27) can also give rise to IL-21-expressing cells, albeit to a much lesser extent than IL-12.<sup>11,17,22</sup> When STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells were exposed to these cytokines, they were unable to up-regulate IL-21

expression (Figure 4C). Thus, although mutations in *STAT3* substantially reduced the ability of IL-12 to induce IL-21 expression in CD4<sup>+</sup> T cells, the ability of IL-6, IL-21, IL-23, and IL-27 to do this was completely dependent on STAT3. Consistent with this, STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells preactivated with IL-6, IL-21, or IL-23 were unable to support Ab production by cocultured B cells (supplemental Figure 3E-F).

## Discussion

Lymphocyte differentiation is the outcome of the integration of signals from numerous external stimuli and the activation of specific transcription factors that regulate gene expression and ultimately cellular function. The differentiation of naive CD4<sup>+</sup> T cells into Th1, Th2, Th17, and T-regulatory cells has been well-characterized for the roles of specific cytokines and transcription factors. The emergence of Tfh cells as the predominant subset of CD4<sup>+</sup> T cells that mediate TD humoral immunity has been accompanied by the elucidation of the requirements for their generation and maintenance. Thus, engaging the TCR, ICOS, and the SLAM/SAP pathways by ligands present on APCs, together with signals mediated by STAT3 downstream of receptors for the cytokines IL-6, IL-21, and IL-27, coordinately induce expression of the transcription factors BCL6, IRF4, and c-MAF, which converge to yield Tfh cells.<sup>8,12</sup> Despite these generalized findings, much controversy remains over the relative contribution of these individual components to Tfh cell formation; this is most apparent from subsequent studies that have challenged the role of IL-6 and IL-21 in this process.<sup>8,12,18,19</sup> Furthermore, the molecular requirements for the generation of human Tfh cells remain incompletely defined.

We and others previously showed that IL-12 plays an important role in the differentiation of human Tfh cells, as evidenced by its ability to induce expression of IL-21 and to maintain expression of ICOS and CXCR5 on naive CD4<sup>+</sup> T cells.<sup>11,22</sup> Similar to studies in mice,<sup>7,14,17</sup> IL-6, IL-21, and IL-27 also induce IL-21 expression in human naive CD4<sup>+</sup> T cells, albeit to a much lesser extent than

IL-12.<sup>11,17,22</sup> We have now substantially extended these findings by investigating the *in vivo* and *in vitro* development of T<sub>H</sub> cells in patients with loss-of-function mutations in *IL-12RB1*, *STAT1*, *TYK2*, and *STAT3*; that is genes that compromise cytokine-mediated intracellular signaling pathways probably involved in regulating human T<sub>H</sub> cell formation.

The specific ability of IL-12 to induce IL-21 expression in human naive CD4<sup>+</sup> T cells was confirmed by showing that in the absence of a functional receptor (ie, in patients deficient for IL-12Rβ1) IL-12 was unable to give rise to IL-21-expressing cells (Figure 11). Interestingly, IL-12-mediated IL-21 expression partially depended on intact STAT3 signaling, because heterozygous mutations in *STAT3* (which render most STAT3 dimers nonfunctional) reduced IL-21 expression by 50%-75%. Induction of IL-21 expression in CD4<sup>+</sup> T cells by IL-12 was also reduced in the absence of *TYK2* but was unaffected by *STAT1* deficiency. Further evidence that the generation of human T<sub>H</sub> cells is *STAT1* independent was the finding that the frequency of circulating CXCR5<sup>+</sup>CD45RA<sup>-</sup> T cells was unaffected by gain-of-function mutations in *STAT1* (22% ± 6.6%; n = 3). Although IL-12 is well-characterized for its ability to operate via *STAT4*-dependent pathways,<sup>20</sup> our finding of a requirement for *STAT3* in IL-12 function is consistent with numerous studies that have documented *STAT3* activation in human and murine T cells exposed to IL-12.<sup>21,33,34,38,42</sup> *TYK2* is similarly phosphorylated in IL-12-treated T cells.<sup>20,38,39</sup> Despite the defect in IL-21 production, IL-12 could still induce *STAT3*<sub>MUT</sub> naive CD4<sup>+</sup> T cells to acquire other characteristics of T<sub>H</sub> cells such as increased expression of *ICOS*, *CXCR5*, and *BCL6* (Figure 5A-D). The intact induction of these phenotypic and molecular changes in T<sub>H</sub>-like cells, as well as residual expression of IL-21, in IL-12-treated CD4<sup>+</sup> T cells derived from *STAT3*<sub>MUT</sub> patients, are probably induced in a *STAT4*-dependent manner. Thus, IL-12 induces IL-21 expression predominantly through a *TYK2/STAT3*-dependent mechanism, with a minor contribution via *STAT4* signaling. This is supported by the ability of both *STAT3* and *STAT4* to bind the promoters of the *IL21* and *BCL6* genes<sup>43,44</sup> and also by the recent finding that IL-12 induces IL-21 in murine CD4<sup>+</sup> T cells via *STAT3*- and *STAT4*-dependent pathways.<sup>42</sup> Importantly, the reduction in IL-12-induced expression of IL-21 in *STAT3*<sub>MUT</sub> CD4<sup>+</sup> T cells translated to a functional defect in TD B-cell differentiation *in vitro* (Figure 6). Interestingly, although IL-12 could still induce normal levels of *ICOS* on *STAT3*<sub>MUT</sub> CD4<sup>+</sup> T cells, this could not compensate for the deficiency in IL-21 production by these T cells, which is the primary source of help for B-cell differentiation. These findings are consistent with a model in which *ICOS* has a dual role in T<sub>H</sub> cells, first, in their generation from naive precursors, and second, in enhancing IL-21 expression.<sup>12,14,45,46</sup>

While the ability of IL-12 to induce IL-21 in naive CD4<sup>+</sup> T cells was predominantly *STAT3*-dependent, induction of IL-21 by IL-6, IL-21, and IL-27; and the ability of CD4<sup>+</sup> T cells primed with these cytokines to help B cells, were completely abrogated by mutations in *STAT3*. Thus, the ability of all cytokines currently identified to induce IL-21 in human CD4<sup>+</sup> T cells, and subsequent B cell-helper function would be dramatically affected by *STAT3* mutations, that is, either strongly reduced or completely abolished. The importance of intact *STAT3* signaling in generating human T<sub>H</sub> cells is reinforced by the significant reduction in the frequencies of circulating CD4<sup>+</sup> CXCR5<sup>+</sup> T cells in *STAT3*<sub>MUT</sub> patients. By contrast, the frequency of these CXCR5<sup>+</sup> T<sub>H</sub>-like cells was normal in patients deficient for IL-12Rβ1. This suggests that, although IL-12 induces the greatest frequency of IL-21-expressing CD4<sup>+</sup> T cells, there is sufficient redundancy among cytokine signaling pathways involved in generating T<sub>H</sub> cells to overcome the inability of CD4<sup>+</sup> T cells to give rise to T<sub>H</sub> cells in the absence of the IL-12 signaling. In other words, IL-6, IL-21, and IL-27 signaling

through *STAT3* will still give rise to T<sub>H</sub> cells from *IL12RB1*-mutant CD4<sup>+</sup> T cells. This is supported by the observation that humoral immune responses are intact in patients deficient for IL-12Rβ1.<sup>26,30,31</sup> Given the critical role of T<sub>H</sub> cells in humoral immune responses, it makes teleologic sense that this level of redundancy evolved to protect against the detrimental effects of T<sub>H</sub> cell deficiency. In contrast, use of *STAT3* by several cytokines in the generation of human T<sub>H</sub> cells provides an explanation for why *STAT3*<sub>MUT</sub> patients exhibit defects in humoral immune responses (including reductions in circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> T<sub>H</sub>-like cells, memory B cells and an inability to mount protective Ab responses after vaccination or natural infection<sup>24,47,48</sup>) that cannot be compensated entirely by IL-12-dependent *STAT4* signaling. These clinical, cellular, and serologic features of *STAT3* deficiency are reminiscent of patients with mutations in *ICOS* and *CD40LG*,<sup>49,50</sup> which largely result from an absence of B-cell help by T<sub>H</sub> cells.<sup>49,50</sup> Thus, although an intrinsic defect resulting from the inability of B cells to respond to cytokines such as IL-6, IL-10, and IL-21 would contribute to the functional Ab deficiency in *STAT3*<sub>MUT</sub> patients,<sup>24</sup> this defect would be compounded further by the compromised generation and function of T<sub>H</sub> cells.

Overall, our findings have shed substantial light on the molecular requirements for generating human T<sub>H</sub> cells and have identified a signaling pathway that could be targeted to enhance T<sub>H</sub> cell generation in immunodeficient conditions. The corollary is that because dysregulated activation and/or generation of T<sub>H</sub> cells has been associated with autoimmunity in humans and mice, inhibiting this pathway may represent a novel approach to treating autoAb-mediated conditions.

## Acknowledgments

The authors thank the Garvan Flow Cytometry facility for cell sorting, Dr Rene de Waal Malefyt (DNAX) for providing reagents (IL-4, anti-IL-4 mAb), and the patients and their families for participating in this project.

This work was supported by project and program grants from the National Health and Medical Research Council (NHMRC) of Australia (C.S.M., E.K.D., M.B., D.A.F., M.C.C., and S.G.T.) and Rockefeller University Center for 541 Clinical and Translational science (SUL1RR024143; J.-L.C.). C.S.M. is a recipient of a Career Development Fellowship and S.G.T. is a recipient of a Senior Research Fellowship from the NHMRC of Australia.

## Authorship

Contribution: C.S.M. designed the research, performed experiments, analyzed and interpreted results, and wrote the manuscript; D.T.A., A.C., and E.K.D. performed experiments; J.B., S.B.-D., P.D.A., A.Y.K., D.A., D.E., K.M., S.S.K., Y.M., S.N., M.A.F., S.C., J.M.S., J.P., M.W., P.G., M.C.C., D.A.F., and J.-L.C. provided patient samples and clinical details; M.C.C. also genotyped *STAT3*-mutant patients; M.B. provided intellectual input; and S.G.T. designed the research, interpreted results, and wrote the manuscript. All authors commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Cindy S. Ma, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, 2010 NSW, Australia; e-mail: c.ma@garvan.org.au; or Stuart G. Tangye, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, 2010 NSW, Australia; e-mail: s.tangye@garvan.org.au.